NZ322369A - Use of phosphorylated BETA H.influenzae - Google Patents

Use of phosphorylated BETA H.influenzae

Info

Publication number
NZ322369A
NZ322369A NZ322369A NZ32236996A NZ322369A NZ 322369 A NZ322369 A NZ 322369A NZ 322369 A NZ322369 A NZ 322369A NZ 32236996 A NZ32236996 A NZ 32236996A NZ 322369 A NZ322369 A NZ 322369A
Authority
NZ
New Zealand
Prior art keywords
casein
recombinant human
phosphorylated recombinant
influenzae
spray
Prior art date
Application number
NZ322369A
Other languages
English (en)
Inventor
Pradip Mukerji
Jennifer M Thurmond
Lennart Hansson
Jeffrey H Baxter
Robert G Hards
Amanda Eun-Yeong Leonard
Steven N Anderson
Linda A Harvey
Original Assignee
Abbott Lab
Symbicom Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab, Symbicom Ab filed Critical Abbott Lab
Publication of NZ322369A publication Critical patent/NZ322369A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4732—Casein
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Dairy Products (AREA)
NZ322369A 1995-11-06 1996-11-06 Use of phosphorylated BETA H.influenzae NZ322369A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55252995A 1995-11-06 1995-11-06
PCT/US1996/017860 WO1997017085A2 (en) 1995-11-06 1996-11-06 A method for inhibiting attachment of h. influenzae to human cells using phosphorylated recombinant human beta-casein

Publications (1)

Publication Number Publication Date
NZ322369A true NZ322369A (en) 1999-11-29

Family

ID=24205731

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ322369A NZ322369A (en) 1995-11-06 1996-11-06 Use of phosphorylated BETA H.influenzae

Country Status (6)

Country Link
EP (1) EP0862450A2 (ja)
JP (1) JP2000500141A (ja)
AU (1) AU7610496A (ja)
MX (1) MX9803565A (ja)
NZ (1) NZ322369A (ja)
WO (1) WO1997017085A2 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942254A (en) * 1995-02-27 1999-08-24 Abbott Laboratories Phosphorylated recombinant human β-casein expressed in a bacterial system
ATE246934T1 (de) * 1995-11-06 2003-08-15 Abbott Lab Phosphoryliertes rekombinantes menschliches beta- kasein für die hemmung der anheftung von h. influenzae an menschlichen zellen
EP1572115B1 (en) 2002-11-27 2015-01-21 Ampio Pharmaceuticals, Inc. Treatment of diseases and conditions mediated by increased phosphorylation
US7332179B2 (en) 2003-12-12 2008-02-19 Kimberly-Clark Worldwide, Inc. Tissue products comprising a cleansing composition
US7642395B2 (en) 2004-12-28 2010-01-05 Kimberly-Clark Worldwide, Inc. Composition and wipe for reducing viscosity of viscoelastic bodily fluids

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE465109B (sv) * 1989-10-30 1991-07-29 Bengt Andersson Antibakteriell komposition
US5795611A (en) * 1989-12-20 1998-08-18 Slattery; Charles W. Human infant formulas containing recombinant human alpha-lactalbumin and beta-casein
WO1993004171A1 (en) * 1991-08-19 1993-03-04 Symbicom Aktiebolag Human beta-casein, process for producing it and use thereof
WO1994006306A1 (en) * 1992-09-22 1994-03-31 New Zealand Dairy Board A process for producing beta-casein enriched products
JPH10500101A (ja) * 1994-05-26 1998-01-06 アボツト・ラボラトリーズ インフルエンザ菌のヒト細胞への付着の阻害
JPH10500100A (ja) * 1994-05-26 1998-01-06 アボツト・ラボラトリーズ 哺乳動物細胞のｒｓウイルス感染の阻害
US5807702A (en) * 1995-02-27 1998-09-15 Abbott Laboratories Method for expressing phosphorylated recombinant human β-casein in a bacterial system
CA2213734A1 (en) * 1995-02-27 1996-09-06 Abbott Laboratories A plasmid for expressing modified recombinant proteins in a bacterial system
ATE246934T1 (de) * 1995-11-06 2003-08-15 Abbott Lab Phosphoryliertes rekombinantes menschliches beta- kasein für die hemmung der anheftung von h. influenzae an menschlichen zellen

Also Published As

Publication number Publication date
WO1997017085A3 (en) 1997-08-07
MX9803565A (es) 1998-09-30
EP0862450A2 (en) 1998-09-09
WO1997017085A2 (en) 1997-05-15
AU7610496A (en) 1997-05-29
JP2000500141A (ja) 2000-01-11

Similar Documents

Publication Publication Date Title
EP0614616A3 (en) Composition for the treatment of patients with liver diseases.
MY103566A (en) Infant formulas and nutrition products enriched with nucleosides and/or nucleotides and processes for preparation
EP0494972A4 (en) Effervescent dosage form and method of administering same
HUT65754A (en) Process for production of preparations containing complement inhibitors for treatment of inflammatory intestinal-and dermal-diseases
DE69331296D1 (de) Enterale Formel mit einem armen Kaloriengehalt zur Verminderung der Diarrhöe bei Patienten unter Sondennährung
HK1011914A1 (en) Nutritional product for treatment of ulcerative colitis and use thereof
GR3023542T3 (en) Quinolone carboxylic acid--metal ion--acid complexes
ATE145554T1 (de) Verwendung von kurzkettige fettsäuren enthaltenden lipiden zur aufrechterhaltung der integrität und der funktion des magen-darm-kanals
NZ322369A (en) Use of phosphorylated BETA H.influenzae
Larson et al. Frequency of eating as a factor in experimental dental caries
GB9416846D0 (en) Lipid supplementation
HUT49284A (en) Process for production of medical compositions applicable "in loco" against androgene hairlessness
GB8402573D0 (en) Oral formulation
MX9803568A (es) Producto para inhibir la union de h. influenzae a celulas humanas.
FR2387655A1 (fr) Medicament contre la diarrhee a base de charbon, bolus alba, pectine, poudre de petit lait et lactose
MX9605829A (es) Inhibicion de la union del h. influenzae a celulas humanas.
DE3476736D1 (en) Use of an antihypoxidoticum with cerebral and peripheral effect
AU6666490A (en) Method for improving ventilation during sleep and treating sleep related ventilation abnormalities
MX9701979A (es) Inhibicion de infeccion por rotavirus humano.
Roe et al. Vocal stimulation early in life and infant vocal responsiveness to mother vs. stranger: A curvilinear relationship
MX9605830A (es) Inhibicion de la infeccion de las celulas de mamiferos por el virus sincicial respiratorio.
Gemmell Interaction of Clostridium difficile toxin with human polymorphonuclear leukocyte function.
NZ329311A (en) use of beta-casein to inhibit infection in mammalian cells by respiratory syncytial virus
PT75832A (en) Process for the preparation of n-sulphenylated biuret-n''-carboxylic acid esters with pesticidal and bactericidal effect
HU9201483D0 (en) Process for the production of 1h-rh-analogues'acid additive salts, and for the production of medical preparations containing them